Takeda reported that zasocitinib, the TYK2 inhibitor it acquired in a multibillion‑dollar deal, met primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said more than half of treated patients achieved clear or almost clear skin at the four‑month landmark and plans regulatory submissions in 2026. Takeda will disclose full safety and efficacy datasets at an upcoming medical meeting; reported common adverse events included respiratory tract infections and acne. The drug is also being evaluated in multiple other inflammatory indications and in a head‑to‑head with Bristol Myers Squibb’s Sotyktu. The outcome validates a high‑value acquisition strategy and signals intensified competition in oral immunology, where selective TYK2 inhibitors aim to provide oral alternatives to injectable biologics. Payers and competitors will be watching dosing margins, safety profile and positioning relative to existing oral options.